DexCom, Inc.
No mega hedge funds in our coverage currently report a major 13F position in this stock
Coverage: 0.0%
-
Based on SEC 13F filings
🚀DXCM SGDC Quant Rating & Setup
📌 Business Moat Summary:DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
📈8-Quarter Institutional Ownership Evolution
Historical trajectory of institutional holders and allocation weight across the last 8 quarters
🏛️Institutional Investors Holding this Stock
Examine each hedge fund holding this ticker, weight, shares, and recent action
| Manager / Fund | Fund AUM | Weight | Shares Held | Action | Action |
|---|---|---|---|---|---|
| No tracked mega hedge funds currently hold this stock. | |||||
Want to see Wall Street's Top 50 Consensus Buys?
Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.
⚡Planning to trade DXCM?
Add this symbol to your private journal or dividend tracker to monitor institutional moves.